Transcranial Photobiomodulation for Executive Function in Bipolar Disorder
NCT ID: NCT05408637
Last Updated: 2025-08-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
13 participants
INTERVENTIONAL
2022-08-09
2024-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression
NCT00961454
Trial of Transcranial Photobiomodulation for Depression With PET and EEG Outcomes
NCT06934135
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression
NCT04366258
Effects of Transcranial Photobiomodulation in ADHD
NCT07203092
Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder
NCT06274567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will attend a baseline visit during which they will complete mood questionnaires and a gambling task. Participants will then receive five treatments of transcranial light therapy over one week. The first and last of these treatments will be administered while the participant is in an MRI scanner. At the first visit, participants will also receive a "sham" tPBM treatment, meaning that the device will simulate real treatment, but will not actually apply the near-infrared light. The check-in call will occur approximately 2-3 days after the final treatment visit. This will be a brief call with a study clinician to check-in on the participant's mental and physical health. The follow up visit will occur approximately one week after the final visit. Subjects will be asked to complete mood questionnaires and/or gambling tasks during the first and fifth treatment visits, as well as at the follow up visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Phoobiomodulation (tPBM)
Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of bipolar disorder
* Currently experiencing symptoms of impulsivity
* Vision normal or corrected to normal with contacts
Exclusion Criteria
* Currently psychotic
* Judged to be at serious and imminent suicidal risk
* Currently in alcohol or substance use disorder (meeting criteria in the past 3 months)
* Unstable medical conditions
* Inability to consent or to complete study procedures
* Failure to meet standard MRI safety requirements (e.g. claustrophobia, non-removable piercings, implanted medical devices, other non-removable metals)
* Changes in medications or use of augmentative devices and other interventions in the 2 weeks prior to the study
* Participation in other clinical research trials that may influence primary outcomes or adherence to the proposed study
* Current pregnancy.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paolo Cassano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paolo Cassano
Director of Photobiomodulation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mass General Hospital Navy Yard Building 149
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022p000289
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.